Все публикации

Download this brief resource with clinical pearls related to testing and targeted treatment for BRAF V600E–mutant mCRC and mNSCLC.

Download these slides from a recent educational program to determine optimal subcutaneous immunotherapy strategies and improve clinical outcomes for patients with solid tumors.

Enhance your knowledge and optimize treatment for patients with R/R MM by learning from subject matter experts Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, in this podcast. Listen as they discuss various strategies to optimize the use of bispecific antibodies in their practices through patient monitoring, dosing in outpatient settings, and utilizing tocilizumab and IVIG among other management strategies.

Experts answer your questions related to the program, “Beyond CIT: Uniting Patient Voices With the Latest Evidence on Novel Targeted Therapies for CLL/SLL.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program.

In this commentary, disease experts discuss how optimizing clinical processes, including biomarker testing workflows, treatment sequencing, toxicity management, and multidisciplinary coordination, can improve the safe and effective use of immunotherapy for patients with advanced NSCLC.

Experts answer your questions related to the program, “Beyond Resistance: Integrating Next-Generation SERDs into Community Management of ER-Positive/HER2-Negative Advanced Breast Cancer.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program.

Download these slides from a recent educational program on novel emerging strategies to improve the management of patients with multiple myeloma.

In this commentary, an expert addresses key questions on evolving frontline therapy strategies, counseling patients about stem cell transplant, and individualizing treatment decisions in multiple myeloma.

In this expert commentary, the evolving landscape of mCRPC is examined, with a focus on the biological rationale, clinical evidence, and implementation challenges of novel targeted therapies and precision medicine approaches.

Downloadable slides on best practices for anti-CD38–based treatments for smoldering and newly diagnosed multiple myeloma, including risk stratification, emerging clinical trial data, and transplant-eligible therapy approaches.